Author： Mirochnik Yelena Rubenstein Marvin Guinan Patrick
Publisher： Informa Healthcare
ISSN： 1521-0464
Source： Drug Delivery, Vol.11, Iss.3, 2004-05, pp. : 161-167
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
We evaluated the ability of antibody-derived delivery vehicles (DVs) to direct synthetic biotinylated oligodeoxynucleotides (ODNs) to prostate tumors in vitro. A monoclonal mouse antibody raised against prostate-specific antigen (PSA) was modified by two approaches to produce either: (1) a bispecific delivery vehicle recognizing both PSA and biotin (DVHc), or (2) an avidin-conjugated anti-PSA delivery vehicle (DVPSA). Immunoreactivity of the DVs and their ability to form complexes were tested in vitro. Although both DVs retained immunoreactivity and were able to form complexes with biotinylated ODNs, the avidin modification method was more efficient. This method may be useful for selective delivery of antisense ODNs to prostate tumors.
Related content
Access to resources
Recommend
Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 7, 2000-12 ,pp. :
By Peng Zheng-Hong Sima Monika Salama Mohamed E. Kopečková Pavla Kopeček Jindřich
Journal of Drug Targeting, Vol. 21, Iss. 10, 2013-12 ,pp. :